Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease

Medical Science Monitor

Volumn 11, Issue 1, 2005, Pages

  Watanabe, Yu ^a   Himeda, Toshiki ^a   Araki, Tsutomu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Dopamine transporter; Dopaminergic cells; Glial cells; Neurodegeneration; S100 protein

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE TRANSPORTER; NEUROTOXIN; PROTEIN S100B;

BODY POSTURE; BRADYKINESIA; CLINICAL FEATURE; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; GLIA CELL; NERVE INJURY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; REVIEW; RIGIDITY; TREMOR;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; MICE; MPTP POISONING; NERVE TISSUE PROTEINS; NEUROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; SUBSTANTIA NIGRA;

EID: 12244300931     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Olanow CW, Tatton WG: Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci, 1999; 22: 123-44
2. Fahn S, Przedborski S: Parkinsonism. In: Rowland LP Ed, Merritt's neurology. New York, Lippincott Williams & Wilkins Press, 2000; 679-93
3. Bernheimer H, Birkmayer W, Hornykiewicz O et al: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci, 1973; 20: 415-55
4. Agid Y: Parkinson's disease: pathophysiology. Lancet, 1991; 337: 1321-24
5. Heikkila RE, Hess A, Duvoisin RC: Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science, 1984; 224: 1451-53
6. Schneider JS, Markham CH: Neurotoxic effects of N-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase immunohistochemistry. Brain Res, 1986; 373: 258-67
7. Arai N, Misugi K, Goshima Y, Misu Y: Evaluation of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res, 1990; 515: 57-63
8. Hantraye P, Brouillet E, Ferrante R et al: Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in Baboons. Nat Med, 1996; 2: 1017-21
9. Araki T, Kumagai T, Tanaka K et al: Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res, 2001; 918: 176-81
10. Araki T, Mikami T, Tanji H et al; Biochemical and immunohistochemical changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci, 2001; 12: 231-38
11. Kohutnicka M: Involvement of microgiial cells in the pathogenesis of Parkinson's disease: A mice model induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Med Sci Monit, 1998; 4: 328-36
12. Tipton KF, Singer TP: Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem, 1993; 61: 1191-206
13. Vyas I, Heikkila RE, Nicklas WJ: Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem, 1986; 46; 1501-7
14. Scotcher KP, Irwin I, DeLanney LE et al: Effects of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridium ion on ATP levels of mouse brain synaptosomes. J Neurochem, 1990; 54: 1295-301
15. Gluck MR, Krueger MJ, Ramsay RR et al: Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. J Biol Chem, 1994; 269: 3167-74
16. Hasegawa E, Takeshige K, Oishi T et al: 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun, 1990; 170: 1049-55
17. Chiueh CC, Miyake H, Peng MT: Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol, 1993; 60: 251-58
18. Chiueh CC, Rauhala P: Free radicals and MPTP-induced selective destruction of substantia nigra compacta neurons. Adv Pharmacol, 1998; 42: 796-800
19. Muthane U, Ramsay KA, Jiang H et al: Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp Neurol, 1994; 126; 195-204
20. Wu DC, Jackson-Lewis V, Vila M et al: Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci, 2002; 22: 1763-71
21. Chiba K, Trevor A, Castagnoli N Jr: Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun, 1984; 120: 574-78
22. Pifl C, Giros B, Caron MG: Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci, 1993; 13: 4246-53
23. Schulz JB, Matthews RT, Muqit MM et al: Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem, 1995; 64: 936-39
24. Przedborski S, Jackson-Lewis V, Yokoyama R et al: Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA, 1996; 93; 4565-71
25. Rauen T, Fischer F, Wiessner M: Glia-neuron interaction by high-affinity glutamate transporters in neurotransmission. Adv Exp Med Biol, 1999; 468: 81-95
26. Barres BA: New roles for glia. J Neurosci, 1991; 11: 3685-94
27. Porter JT, McCarthy KD; Astrocytic neurotransmitter receptors in situ and in vivo. Prog Neurobiol, 1997; 51: 439-55
28. Verkhratsky A, Orkand RK, Kettenmann H: Glial calcium: homeostasis and signaling function. Physiol Rev, 1998; 78: 99-141
29. Barres BA: Glial ion channels. Curr Opin in Neurobiol, 1991; 1: 354-59
30. Coles JA, Abbott NJ: Signalling from neurons to glial cells in invertebrates. Trends Neurosci, 1996; 19: 358-62
31. Tsacopoulos M, Magistretti PJ: Metabolic coupling between glia and neurons. J Neurosci, 1996; 16: 877-85
32. Newman E, Reichenbach A: The Muller cell: a functional element of the retina. Trends Neurosci, 1996; 19: 307-12
33. Pfrieger FW, Barres BA: Synaptic efficacy enhanced by glial cells in vitro. Science, 1997; 277: 1684-87
34. Nawashiro H, Brenner M, Fukui S et al: High susceptibility to cerebral ischemia in GFAP-null mice. J Cereb Blood Flow Metab, 2000; 20: 1040-44
35. Dringen R, Pfeiffer B, Hamprecht B: Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci, 1999; 19: 562-69
36. Wang XF, Cynader MS: Astrocytes provide cysteine to neurons by releasing glutathione. J Neurochem, 2000; 74: 1434-42
37. Van Eldik LJ, Ehrenfried B, Jensen RA: Production and characterization of monoclonal antibodies with specificity for the S100 beta polypeptide of brain S100 fractions. Proc Natl Acad Sci USA, 1984; 81: 6034-38
38. Zimmer DB, Cornwall EH, Landar A, Song W; The S100 protein family: history, Function, and expression. Brain Res Bull, 1995; 37: 417-29
39. Reeves RH, Yao J, Crowley MR et al: Astrocytosis and axonal proliferation in the hippocampus of S100? transgenic mice. Proc Natl Acad Sci USA, 1994; 91: 5359-63
40. Griffin WS, Stanley LC, Ling C et al: Brain interleuikin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA, 1989; 86: 7611-15
41. Sheng JG, Mrak RE, Griffin WS: Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta Neuropathol, 1997; 94: 1-5
42. Migheli A, Cordera S, Bendotti C et al: S-100β protein is upregulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett, 1999; 261: 25-28
43. Selinfreund RH, Barger SW, Pledger WJ, Van Eldik LJ: Neurotrophic protein S100 beta stimulates glial cell proliferation. Proc Natl Acad Sci USA, 1991; 88: 3554-58
44. Whitaker-Azmitia PM, Wingate M, Borella A et al: Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: implications for Alzheimer's disease and Down's syndrome. Brain Res, 1997; 776: 51-60
45. Muramatsu Y, Kurosaki R, Watanabe H et al: Expression of S-100 protein is related to neuronal damage in MPTP-treated mice. Glia, 2003; 42: 307-13
46. Kurosaki R, Muramatsu Y, Michimata M et al: Role of nitric oxide synthase against MPTP neurotoxicity in mice. Neurol Res, 2002; 24: 655-62
47. Muramatsu Y, Kurosaki R, Mikami T et al: Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice. Metab Brain Dis, 2002; 17: 169-82
48. Matstii T, Mori T, Tateishi N et al: Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part I: enhanced astrocytic synthesis of s-100beta in the periinfarct area precedes delayed infarct expansion. J Cereb Blood Flow Metab, 2002; 22: 711-22
49. Tateishi N, Mori T, Kagamiishi Y et al: Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab, 2002; 22: 723-34
50. Cheramy A, Leviel V, Glowinski J: Dendritic release of dopamine in the substantia nigra. Nature, 1981; 289: 537-42
51. Nissbrandt H, Sundstrom F, Jonsson G et al: Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and stratum. J Neurochem, 1989; 52: 1170-82
52. Giros B, Caron MG: Molecular characterization of the dopamine transporter. Trends Pharmacol Sci, 1993; 14: 43-49
53. Giros B, Jaber M, Jones SR et al: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 1996; 379: 606-12
54. Kantor L, Gnegy ME: Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther, 1998; 284: 592-98
55. Kopin IJ, Markey SP: MPTP toxicity: implications for research in Parkinson's disease. Annu Rev Neurosci, 1988; 11: 81-96
56. Zigmond MJ, Abercrombie ED, Berger TW et al: Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci, 1990; 13: 290-96
57. Kitayama S, Shimada S, Uhl GR: Parkinsonism-inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann Neurol, 1992; 32: 109-11
58. Niznik HB, Fogel EF, Fassos FF, Seeman P: The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem, 1991; 56: 192-98
59. 3H]mazindol. Neuroscience, 1992; 49: 317-27
60. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG: Dopamine transporter is required in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter. J Neurochem, 1997; 69: 1322-25
61. Bezard E, Gross CE: Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol, 1998; 55: 93-116
62. Bezard E, Gross CE, Fournier MC et al: Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol, 1999; 155: 268-73
63. Tanji H, Araki T, Nagasawa H, Itoyama Y: Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP. Brain Res, 1999; 824: 224-31
64. Betarbet R, Turner R, Chockkan V et al: Dopaminergic neurons intrinsic to the primate striatum. J Neurosci, 1997; 17: 6761-68
65. Ciliax BJ, Drash GW, Staley JK et al: Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol, 1999; 409: 38-56
66. Watanabe H, Muramatsu Y, Kurosaki R et al: Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study. Eur Neuropsychopharmacol, 2004; 14: 93-104
67. Cosi C: Implication of PARP in neurodegeneration and PARP inhibitors as potential. Med Sci Monit, 2003; 9(Suppl.1): 15